Chronic Myeloid Leukemia – Current Treatment – Detailed, Expanded Analysis (US)
The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients to live a normal life span. This improvement in survival, coupled with the aging U.S. population, has increased the prevalence of CML. However, compliance issues with treatments that require lifelong use contribute significantly to drug resistance, fueling the demand for effective and safe second- and later-line therapies. In October 2021, Novartis’s Scemblix launched for the third- and later-line treatment of chronic CML. This first-in-class allosteric inhibitor of ABL/BCR-ABL1 is approved to treat chronic CML patients with the T315I mutation.
Questions answered
• What are the CML treatment rates across the various settings and lines of therapy?
• How are newer therapies for CML performing relative to more-established therapies?
• What are the main drivers of and key obstacles to prescribing select therapies, according to surveyed physicians?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Market covered: United States
Primary research: Survey of 103 U.S. hematologist-oncologists
Key drugs covered: Imatinib, Bosulif, Iclusig, Scemblix, Sprycel, Synribo, Tasigna
Kiran Bountra, M.Res., Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Bountra has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.
Charlotte Jago, Ph.D., Senior Healthcare Research & Data Analyst, Oncology. Dr. Jago is a pharmaceutical industry analyst with more than 18 years’ experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.